STOCK TITAN

Science 37 to Participate in H.C. Wainwright 25th Annual Global Investment Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
Science 37 Holdings, Inc. to participate in H.C. Wainwright 25th Annual Global Investment Conference
Positive
  • None.
Negative
  • None.

RESEARCH TRIANGLE PARK, N.C., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Science 37 Holdings, Inc. (Nasdaq: SNCE), the industry-leading Metasite™, today announced the company will be participating in the upcoming H.C. Wainwright 25th Annual Global Investment Conference on Monday, September 11, 2023.

A recording of the event will be available at 7:00am ET on September 11, 2023 on the investor relations section of Science 37’s website at: https://investors.science37.com and will be archived for 90 days.

About Science 37

Science 37 Holdings, Inc.’s (Nasdaq: SNCE) mission is to accelerate clinical research by enabling universal trial access for patients. As a single Metasite™ Science 37 reaches an expanded patient population beyond the traditional site and delivers the recruiting power of up to 20 sites in one with greater patient diversity. Patients gain the flexibility to participate from the comfort of their own home, at their local community provider, or at a traditional site when needed. The Science 37 Metasite is powered by a proprietary technology platform, in addition to in-house investigators, mobile nurses, and remote coordinators that drive uniform study orchestration, enabling greater compliance and high-quality data. To learn more, visit www.science37.com, or email science37@science37.com.

Contacts:

MEDIA INQUIRIES:
Grazia Mohren
Science 37
Email: pr@science37.com

INVESTOR RELATIONS:
Steve Halper
LifeSci Advisors
Email: shalper@lifesciadvisors.com


Science 37 Holdings, Inc.

NASDAQ:SNCE

SNCE Rankings

SNCE Latest News

SNCE Stock Data

34.66M
4.13M
16.89%
52.18%
0.23%
Testing Laboratories
Professional, Scientific, and Technical Services
Link
United States
Research Triangle Park

About SNCE

science 37 uses advanced telemedicine technology and patient-centric innovative networked clinical research models to rapidly accelerate biomedical discovery and bring down the costs of clinical trials. in addition to our own researchers, we also work closely with top physician-scientists and leading telemedicine companies. s37 offers full support and end-to-end services for networked clinical trials. if you are an investigator, an inventor, a small biotech company or a large pharmaceutical company, we can help you achieve your clinical trial goals faster and easier than ever before. based in los angeles, we are focused on the development of networked patient-centric models for clinical research to rapidly accelerate biomedical discovery. we leverage partnerships with national mobile nursing companies, pharmacy chains, patient advocacy groups, virtual e-consenting, mobile devices, and other technology companies to maximize efficiency. then, using design-thinking principles and rapid pr